10.1161/ATVBAHA.119.313200 Arterioscler Thromb Vasc Biol
1000 , 3
As the SELECT trial nears completion, a similar large trial was launched in autumn 2022, but this one involves a new wrinkle on GLP-1 receptor agonism that appears to yield even greater weight loss
In the U.S, about 70% of adults are obese or overweight, and many of these people have serious health problems that put them at greater risk for heart disease, stroke, diabetes and some types of cancer
Choline falls into the latter category, with research suggesting that our livers production of choline is not enough to meet our daily needs
Semaglutide is a GLP-1 receptor agonist that primarily acts on receptors in the brain (appetite regulation), pancreas (insulin secretion), and gastrointestinal tract (gastric emptying)